The developer of Russias Sputnik V COVID-19 vaccine stated that it had entered into a partnership with an Indian drugmaker to produce 200 million doses of the vaccine. 

The Russian Direct Investment Fund (RDIF) released a statement that it had partnered with Stelis Biopharma for production and supply of at least 200 million doses of the Russian Sputnik V vaccine. The Indian drugmaker is expected to start supplying the vaccine from the second half of 2021.

RDIF stated that 52 countries have approved the use of Sputnik V vaccine. Moscow registered the vaccine in August before large-scale clinical trials, and the medical journal The Lancet has also stated that the jab is safe and more than 90% effective… (NDTV - Agence France-Presse, March 19, 2021)